Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab with Pomalidomide, Carfilzomib and Dexamethasone in High-Risk RRMM
NCT03104270Phase 2Terminated
- Sponsor
- ONCOtherapeutics
- Start
- Mar 2017
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elotuzumab in multiple myeloma (MM), sponsored by ONCOtherapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 34 months and Overall Rate of Response at 34 months. Started Mar 2017; status: terminated.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03104270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104270.